Tirzepatide for Sleep Apnea: The SURMOUNT-OSA Evidence
SURMOUNT-OSA showed tirzepatide significantly reduced the severity of obstructive sleep apnea in adults with obesity, leading to FDA approval of Zepbound for moderate-to-severe OSA in 2024 — the first drug approved for the condition. The benefit is tied to weight loss and applies to brand Zepbound, which became the first drug FDA-approved for obstructive sleep apnea in 2024; compounded tirzepatide was not studied for this use.
- SURMOUNT-OSA tested tirzepatide in adults with obesity and moderate-to-severe OSA.
- Tirzepatide markedly reduced apnea-hypopnea index (AHI) vs placebo.
- Zepbound became the first drug FDA-approved for OSA (2024).
- The approval is for the brand product, not compounded tirzepatide.
What SURMOUNT-OSA tested
SURMOUNT-OSA was a pair of randomized trials testing tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea (OSA), a condition in which the airway repeatedly collapses during sleep. One trial studied patients using CPAP therapy and one studied patients not using it.
The primary measure was the apnea-hypopnea index (AHI), the number of breathing interruptions per hour of sleep — the standard metric of OSA severity.
The trials asked whether tirzepatide, by producing substantial weight loss, could meaningfully reduce OSA severity.
The results
Tirzepatide produced a large reduction in AHI compared with placebo in both trials, substantially decreasing the number of breathing interruptions per hour. Many participants improved enough to change their OSA severity category, and some met criteria for disease resolution.
The improvements accompanied significant weight loss, consistent with the understanding that excess weight is a major driver of OSA in many patients.
These results led the FDA to approve Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity in late 2024, the first medication ever approved for the condition.
| Element | Detail |
|---|---|
| Population | Adults with obesity + moderate-severe OSA |
| Measure | Apnea-hypopnea index (AHI) |
| Result | Large AHI reduction vs placebo |
| Outcome | Zepbound FDA-approved for OSA (2024) |
What it means for patients
For patients with obesity and OSA, this evidence offers a medication option that treats both conditions at once. It does not necessarily replace CPAP for everyone, but it gives clinicians a new tool, especially for patients who struggle with CPAP adherence.
The approval is specific: moderate-to-severe OSA in adults with obesity. It is not a general sleep aid, and its benefit is tied to the weight loss and metabolic effects of tirzepatide.
Patients should view it as part of a broader OSA management plan directed by their clinician, not a standalone cure.
Compounded tirzepatide and OSA
The SURMOUNT-OSA evidence and the FDA approval apply to the brand product, Zepbound. Compounded tirzepatide was not studied for OSA and is not approved for it.
As with other GLP-1 evidence, the trial results attach to the specific approved product, not to every preparation containing the molecule. It is not valid to assume a compounded product delivers the same OSA benefit.
A patient specifically seeking OSA treatment has a strong reason to discuss the approved product with a clinician.
| Applies to | Does not apply to |
|---|---|
| Brand Zepbound for OSA | Compounded tirzepatide for OSA |
| Adults with obesity + OSA | General sleep complaints |
The bottom line
SURMOUNT-OSA showed tirzepatide significantly reduces obstructive sleep apnea severity in adults with obesity, leading to Zepbound's 2024 approval as the first drug for OSA.
The benefit is tied to weight loss and applies to the approved brand product, not compounded tirzepatide. It is a new option within OSA management, not a universal replacement for CPAP.
This is educational information; OSA treatment decisions belong with your clinician.
Frequently asked questions
What did SURMOUNT-OSA show?
Tirzepatide significantly reduced obstructive sleep apnea severity (AHI) in adults with obesity, leading to Zepbound's FDA approval for OSA in 2024.
Is tirzepatide approved for sleep apnea?
Zepbound (brand tirzepatide) is FDA-approved for moderate-to-severe OSA in adults with obesity. Compounded tirzepatide is not.
Does it replace CPAP?
Not necessarily. It is a new option, especially for patients who struggle with CPAP, but OSA management should be directed by a clinician.
Does compounded tirzepatide help OSA?
It was not studied for OSA and is not approved for it. The evidence applies to the brand product.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- NEJM — STEP, SELECT, SURMOUNT, SURPASS, SUSTAIN, PIONEER, FLOW, SURMOUNT-OSA trials.
- ClinicalTrials.gov and prescribing information.
- Evidence policy: evidence policy.